Immunogenicity and safety of acellular pertussis vaccine at birth

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/570756

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Currently, the first dose of a vaccine to protect against pertussis (whooping cough) is not given until 2 months of age, and third dose until 6 months. However, more than 80% of the most severe cases of pertussis (resulting in hospitalisation or death) occur before 6 months. This study aims to show that giving the first dose of pertussis vaccine at birth and the second dose at 6 weeks protects babies at the time they are most likely to die or become severely ill from whooping cough

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $1,508,927.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Preventive Medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Cell mediated immunity | Epidemiology | Immune response | Immunisation | Neonatal | Pertussis | Population health | Prevention

Related Links